

BC Cancer Protocol Summary for Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel

Protocol Code: GOENDAVCAT

Tumour Group: Gynecology

Contact Physician: [GO Systemic Therapy](#)

ELIGIBILITY:

Patients must have:

- [Locally advanced or metastatic endometrial carcinoma, not amenable to curative treatment, and](#)
- [Newly diagnosed or recurrent disease, of any molecular sub-type, all histologies*](#)

** Mixed histologies of any component, other than those listed in exclusions below*

EXCLUSIONS:

- Uterine sarcoma or small cell/neuroendocrine carcinoma,
- AST and/or ALT greater than 10 times the Upper Limit of Normal (ULN), or
- Total bilirubin greater than 5 x ULN

CAUTIONS

- Pre-existing motor or sensory neuropathy greater than grade 2
- Performance status greater than ECOG 2

TESTS:

- Baseline: CBC & Diff, creatinine, total bilirubin, ALT
- Baseline, if clinically indicated: CA 125, CA 15-3, CA 19-9, CEA, [sodium, potassium magnesium, calcium, alkaline phosphatase, LDH, GGT](#)
- Before each treatment: CBC & Diff, creatinine, total bilirubin, ALT
- If clinically indicated before each treatment: CA 125, CA 15-3, CA 19-9, CEA, [alkaline phosphatase LDH, GGT, sodium, potassium, magnesium, calcium](#)

PREMEDICATIONS:

- **PACLitaxel must not be started unless the following drugs have been given:**
 - 45 minutes prior to PACLitaxel:
 - dexamethasone 20 mg IV in 50 mL NS over 15 minutes
 - 30 minutes prior to PACLitaxel:
 - diphenhydrAMINE 50 mg IV in NS 50 mL over 15 minutes and famotidine 20 mg IV in NS 100 mL over 15 minutes (Y-site compatible)
- Antiemetic protocol for highly emetogenic chemotherapy protocols (see [SCNAUSEA](#))

TREATMENT:

Drug	Starting Dose	BC Cancer Administration Guideline
PACLitaxel	175 mg/m ² *	IV in 250 to 500 mL NS over 3 hours (use non-DEHP bag and non-DEHP tubing with 0.2 micron in-line filter)
CARBOplatin	Dose = AUC 5 or 6** x (GFR +25)	IV in 100 to 250 mL NS over 30 minutes

* Conservative Paclitaxel dosing (i.e., 155 mg/m² or 135 mg/m²) with escalation up to 175 mg/m² if tolerated may be considered in the following cases: ECOG greater than or equal to 2, existing or potential myelosuppression; existing or potential arthralgia and myalgia; prior radiotherapy, particularly to the pelvic region; reduced bone marrow capacity

** use AUC of 6; if extensive prior radiation therapy, use AUC of 5

Repeat every 21 days for up to 6 cycles

Measured GFR (e.g. nuclear renogram) is preferred in circumstances of co-morbidity that could affect renal function (third-space fluid accumulations, hypoproteinemia, potentially inadequate fluid intake, age greater than 70, etc.). The lab reported GFR (MDRD formula) may be used as an alternative to the Cockcroft-Gault estimate of GFR; the estimated GFR reported by the lab or calculated using the Cockcroft-Gault equation should be capped at 125 mL/min when it is used to calculate the initial CARBOplatin dose. When a nuclear renogram is available, this clearance would take precedence.

Cockcroft-Gault Formula

$$\text{GFR} = \frac{1.04 \times (140 - \text{age in years}) \times \text{wt (kg)}}{\text{serum creatinine (micromol/L)}}$$

Recalculate GFR if, at a point of (optional) checking, creatinine increases by greater than 20% or rises above the upper limit of normal.

DOSE MODIFICATIONS:

1. Hematology:

On treatment day:

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Doses* (both drugs)
Greater than or equal to 1.0	and	Greater than or equal to 100	Proceed at same doses
Less than 1.0	or	Less than 100	Delay until recovery

*Note: If dose has been reduced, dose increase/re-escalation is not recommended.

2. Arthralgia and/or myalgia:

If arthralgia and/or myalgia from PACLitaxel of grade 2 (moderate) or higher was not adequately relieved by NSAIDs or acetaminophen with codeine (e.g., TYLENOL #3), a limited number of studies report a possible therapeutic benefit using:

- predniSONE 10 mg PO bid x 5 days starting 24 hours post-PACLitaxel
- gabapentin 300 mg PO on day before chemotherapy, 300 mg bid on treatment day, then 300 mg tid x 5 to 15 days (based on duration of arthromyalgia)

If arthralgia and/or myalgia persists, reduce subsequent PACLitaxel doses to 135 mg/m² or switch PACLitaxel to DOCEtaxel (GOENDCAD).

3. Neuropathy:

Dose modification or discontinuation may be required (see BC Cancer Drug Manual).

4. Renal dysfunction:

If significant increase (greater than 20% or rises above the upper limit of normal) in creatinine, recheck/recalculate GFR and recalculate CARBOplatin dose using new GFR.

5. Hepatic dysfunction:

reduce PACLitaxel dose:

ALT		Total bilirubin	Dose (mg/m ²)
Less than 10 x ULN	and	Less than or equal to 1.25 x ULN	175
Less than 10 x ULN	and	1.26-2 x ULN	135
Less than 10 x ULN	and	2.01-5 x ULN	90
Greater than or equal to 10 x ULN	and/or	Greater than 5 x ULN	Not recommended

ULN = upper limit of normal

PRECAUTIONS:

1. **Hypersensitivity:** Reactions are common. See BC Cancer Protocol Summary for Management of Infusion-Related Reactions to Chemotherapeutic Agents – [SCDRUGRX](#)

<u>Mild</u> symptoms (e.g. mild flushing, rash, pruritus)	complete PACLitaxel infusion. Supervise at bedside no treatment required
<u>moderate</u> symptoms (e.g. moderate rash, flushing, mild dyspnea, chest discomfort, mild hypotension)	stop PACLitaxel infusion give IV diphenhydrAMINE 25 to 50 mg and hydrocortisone IV 100 mg after recovery of symptoms resume PACLitaxel infusion at 20 mL/hr for 5 minutes, 30 mL/hr for 5 minutes, 40 mL/hr for 5 minutes, then 60 mL/hr for 5 minutes. If no reaction, increase to full rate. if reaction recurs, discontinue PACLitaxel therapy
<u>severe</u> symptoms (i.e. <u>one</u> or more of respiratory distress requiring treatment, generalised urticaria, angioedema, hypotension requiring therapy)	stop PACLitaxel infusion give IV antihistamine and steroid as above. Add epinephrine or bronchodilators if indicated discontinue PACLitaxel therapy

2. **Extravasation:** PACLitaxel causes pain and may, rarely, cause tissue necrosis if extravasated. Refer to BC Cancer Extravasation Guidelines.
3. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
4. **Drug Interactions:** PACLitaxel is a CYP 2C8/9 and CYP 3A4 substrate. Drug levels may be increased by inhibitors of these enzymes and decreased by inducers of these enzymes.

Contact the GO Systemic Therapy physician at your regional cancer centre or GO Systemic Therapy Chair with any problems or questions regarding this treatment program.

References:

1. Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 Nov 20;38(33):3841-3850
2. BC Cancer. Cancer Management Guidelines: Endometrium. Vancouver, Canada: BC Cancer; 2023